Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...
The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...
Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Trav...
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, tod...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced The New England Journal of Medicine ( NEJM ) published the full results from the co...
GSK plc (LSE/NYSE: GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococca...
Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the develo...
Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida&r...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...
GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with ...
© 2025 Biopharma Boardroom. All Rights Reserved.
